Yemen News Agency (SABA)
Home      Revolution Leader   About President   Local   International   US-Saudi Aggression   Economy   Reports   development and community initiatives  
فارسي | Español | Deutsch | Français | عـربي | RSS Feed
Search | Advance Search
 
  Local
Al-Houthi responds to US Central Command's threats: "Yemenis are sea's masters"
[23 December 2024]
Dhamar University Faculty of Medicine organizes introduction to electronic cochlear implant program
[23 December 2024]
Field visit to follow up on implementation of community initiatives in Al-Hodeida
[23 December 2024]
Workflow at Awqaf Office of Sana'a Governorate
[23 December 2024]
Customs Authority supports Joud al-Rahman Orphan Care Foundation
[23 December 2024]
 
  International
Sheikh Sabri: "Jewish holidays show their hidden ambitions towards Al-Aqsa"
[23 December 2024]
Hamas: "We warn against the rhetoric of regional mobilization & its effects on national fabric"
[23 December 2024]
Chinese defense condemns US arms sales to Taiwan
[23 December 2024]
Palestinian woman injured by bullets during enemy forces storming in Husan village
[23 December 2024]
Two martyrs & injuries when enemy targeted group of citizens in Taybeh, south Lebanon
[23 December 2024]
 
  Reports
Yemen & legend deterrence that defeated American project
[23 December 2024]
Training 1,400 farmers in Dhamar across various agricultural sectors: Report
[22 December 2024]
Yemen's weekly flood of support for Palestinian cause
[21 December 2024]
Saudi Arabia Approaches Normalization with Zionist Enemy
[21 December 2024]
Million-Man March in Capital, Governorates: A Challenge to Enemy, Confirmation that Yemen Will Remain Strongest Support Front for Palestine
[21 December 2024]
 
  US-Saudi Aggression
US-British aggression on capital Sana'a
[22 December 2024]
US-British aggression on Hodeida
[22 December 2024]
US aggression targets Al-Ardi complex in Sana'a
[17 December 2024]
US-British aggression aircraft launch raid on Hajjah
[16 December 2024]
US-British aggression targets capital Sana'a
[09 November 2024]
  International
Breakthrough study reveals drug that could halt migraines before they start
Breakthrough study reveals drug that could halt migraines before they start
Breakthrough study reveals drug that could halt migraines before they start
[Tue, 17 Sep 2024 17:00:40 +0300]

NEW YORK - SABA: A recent study has highlighted an exciting new development in migraine treatment. Migraines, affecting billions globally, often bring debilitating headache pain that disrupts daily life.

The latest research reveals that the drug *ubrogepant*, marketed under the brand name *Uberlevi*, might offer a groundbreaking approach by preventing migraines before they fully develop.

The study, funded by the drug's developer AbbVie, explored how *ubrogepant* could be effective if administered at the onset of pre-migraine symptoms—such as sensitivity to light—before the severe headache pain begins.

Traditionally, *ubrogepant* is used to treat migraines once they have started, but this new research tests its efficacy in early intervention.

*Ubrogepant* targets a protein known as CGRP (calcitonin gene-related peptide), which is instrumental in the migraine process.

Neurologist Richard Lipton from Albert Einstein College of Medicine in New York City, who was involved in the study, highlights the potential benefit of addressing migraines at their earliest signs.

"Our findings suggest that *ubrogepant* may allow migraine sufferers to manage their condition more effectively, maintaining their daily routines with less discomfort and disruption," Lipton stated.

In the study, over 400 adults with a history of migraines participated. They were divided into two groups: one received ubrogepant at the onset of pre-migraine symptoms, while the other group received a placebo.

The results were promising: 65% of those who took ubrogepant reported minimal to no restriction from pain 24 hours later, compared to 48% in the placebo group.

Additionally, those on *ubrogepant* experienced faster relief, with many reporting significant improvement within just two hours.

Despite these encouraging outcomes, the study relied on self-reported data rather than objective clinical measurements, and the drug was not effective for every participant every time. Nonetheless, the results offer a hopeful new avenue for managing migraines more proactively.

Improving care at the first signs of a migraine could be crucial for better outcomes," Lipton concluded.

The research suggests that *ubrogepant* could significantly enhance the quality of life for those who suffer from migraines, helping them manage their condition more effectively and maintain their daily activities.


Whatsapp
Telegram
Print

  more of (International)
UPDATED ON :Tue, 24 Dec 2024 00:04:05 +0300